Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Unearthing Hidden Gems: The Top 30 Most Undervalued S&P 500 Stocks for Astute Investors

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

European Experts Back Two AstraZeneca Breakthroughs: New Hope for Rare Diseases

Affiliated Managers Group: Unlocking Value and Safety with Strategic "Baby Bonds"

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

A Major Setback for Amgen: Bemarituzumab's Gastric Cancer Ambitions Dim as Final Data Fails to Impress

Sanofi Stock Plunges as Zantac Lawsuit Risks Re-Emerge Following Key Judicial Ruling